Literature DB >> 23540528

A systematic review of treatment outcomes in pediatric patients with intracranial ependymomas.

Tene A Cage1, Aaron J Clark, Derick Aranda, Nalin Gupta, Peter P Sun, Andrew T Parsa, Kurtis I Auguste.   

Abstract

OBJECT: Ependymoma is the third most common primary brain tumor in children. Tumors are classified according to the WHO pathological grading system. Prior studies have shown high levels of variability in patient outcomes within and across pathological grades. The authors reviewed the results from the published literature on intracranial ependymomas in children to describe clinical outcomes as they relate to treatment modality, associated mortality, and associated progression-free survival (PFS).
METHODS: A search of English language peer-reviewed articles describing patients 18 years of age or younger with intracranial ependymomas yielded data on 182 patients. These patients had undergone treatment for ependymoma with 1 of 5 modalities: 1) gross-total resection (GTR), 2) GTR as well as external beam radiation therapy (EBRT), 3) subtotal resection (STR), 4) STR as well as EBRT, or 5) radiosurgery. Mortality and outcome data were analyzed for time to tumor progression in patients treated with 1 of these 5 treatment modalities.
RESULTS: Of these 182 patients, 69% had supratentorial ependymomas and 31% presented with infratentorial lesions. Regardless of tumor location or pathological grade, STR was associated with the highest rates of mortality. In contrast, GTR was associated with the lowest rates of mortality, the best overall survival, and the longest PFS. Children with WHO Grade II ependymomas had lower mortality rates when treated more aggressively with GTR. However, patients with WHO Grade III tumors had slightly better survival outcomes after a less aggressive surgical debulking (STR+EBRT) when compared with GTR.
CONCLUSIONS: Mortality, PFS, and overall survival vary in pediatric patients with intracranial ependymomas. Pathological classification, tumor location, and method of treatment play a role in outcomes. In this study, GTR was associated with the best overall and PFS rates. Patients with WHO Grade II tumors had better overall survival after GTR+EBRT and better PFS after GTR alone. Patients with WHO Grade III tumors had better overall survival after STR+EBRT. Patients with infratentorial tumors had improved overall survival compared with those with supratentorial tumors. Progression-free survival was best in those patients with infratentorial tumors following STR+EBRT. Consideration of all of these factors is important when counseling families on treatment options.

Entities:  

Mesh:

Year:  2013        PMID: 23540528     DOI: 10.3171/2013.2.PEDS12345

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  20 in total

Review 1.  Supratentorial pediatric cortical ependymomas: a comprehensive retrospective study.

Authors:  Qiguang Wang; Jian Cheng; Si Zhang; Qiang Li; Xuhui Hui; Yan Ju
Journal:  Neurosurg Rev       Date:  2020-06-30       Impact factor: 3.042

Review 2.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Authors:  John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

Review 3.  Current and Emerging Methods of Management of Ependymoma.

Authors:  Sebastian M Toescu; Kristian Aquilina
Journal:  Curr Oncol Rep       Date:  2019-07-29       Impact factor: 5.075

Review 4.  Central nervous system ependymoma: clinical implications of the new molecular classification, treatment guidelines and controversial issues.

Authors:  P D Delgado-López; E M Corrales-García; E Alonso-García; R García-Leal; R González-Rodrigálvarez; E Araus-Galdós; J Martín-Alonso
Journal:  Clin Transl Oncol       Date:  2019-03-13       Impact factor: 3.405

5.  Analysis on therapeutic outcomes and prognostic factors of intracranial ependymoma: a report of 49 clinical cases in a single center.

Authors:  Jingliang Ye; Junle Zhu; Jiayi Yan; Peiqin Chen; Zhiping Wan; Feng Chen; Lei Zhang; Jun Qian; Chun Luo
Journal:  Neurol Sci       Date:  2015-07-28       Impact factor: 3.307

Review 6.  Advances in Management of Pediatric Ependymomas.

Authors:  Frank Y Lin; Murali Chintagumpala
Journal:  Curr Oncol Rep       Date:  2015-10       Impact factor: 5.075

7.  Infratentorial ependymomas--a study of the centre in Katowice.

Authors:  Marek Mandera; Joanna Makarska; Grażyna Sobol; Katarzyna Musioł
Journal:  Childs Nerv Syst       Date:  2015-03-31       Impact factor: 1.475

8.  Posterior fossa ependymoma in childhood: 60 years event-free survival after partial resection—a case report.

Authors:  Tryggve Lundar; Bernt Johan Due-Tønnessen; Bård Krossnes; Paulina Due-Tønnessen; Petter Brandal
Journal:  Childs Nerv Syst       Date:  2015-06-06       Impact factor: 1.475

9.  Vestibular schwannoma or tanycytic ependymoma: Immunohistologic staining reveals.

Authors:  Anthony Divito; Jeffrey T Keller; Matthew Hagen; Mario Zuccarello
Journal:  Surg Neurol Int       Date:  2014-11-12

10.  Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.

Authors:  Asuka Araki; Monika Chocholous; Johannes Gojo; Christian Dorfer; Thomas Czech; Harald Heinzl; Karin Dieckmann; Inge M Ambros; Peter F Ambros; Irene Slavc; Christine Haberler
Journal:  Acta Neuropathol Commun       Date:  2016-08-22       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.